Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

Biofabricated tissues have found numerous applications in tissue engineering and
regenerative medicine in addition to the promotion of disease modeling and drug …

Abstract Around 30–40% of patients with colorectal cancer (CRC) undergoing curative
resection of the primary tumour will develop metastases in the subsequent years. Therapies …

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

Cancer cells are regulated by oncogenic mutations and microenvironmental signals, yet
these processes are often studied separately. To functionally map how cell-intrinsic and cell …

Patient-derived organoids (PDOs) can model personalized therapy responses; however,
current screening technologies cannot reveal drug response mechanisms or how tumor …

Organoids derived from adult stem cells (ASCs) and pluripotent stem cells (PSCs) are
important preclinical models for studying cancer and developing therapies. Here, we review …

Cell state plasticity is carefully regulated in adult epithelia to prevent cancer. The aberrant
expansion of the normally restricted capability for cell state plasticity in neoplasia is poorly …

Chronic inflammation promotes development and progression of colorectal cancer (CRC).
To comprehensively understand the molecular mechanisms underlying the development …

Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7%
of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in …